ロード中...
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
INTRODUCTION: Type 2 diabetes is increasing in prevalence worldwide and is a leading cause of morbidity and mortality, mainly due to the development of complications. Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4), a new class of oral antidiabetic agents. AIMS: To evaluate the role o...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2899806/ https://ncbi.nlm.nih.gov/pubmed/20694081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3355/ce.2008.009 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|